Clinical Trial Update: Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a vaccine therapy with OPT-821 in ovarian epithelial, fallopian tube, or primary peritoneal cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• OPT-821

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Status: WITHDRAWN